New U.S. cancer drug prices rise 53% in five years -report

By Deena Beasley (Reuters) - The annual price of a newly-launched cancer drug in the United States averaged $283,000 last year, a 53% increase from 20...

Related Keywords

California ,United States ,America ,Celgene Idhifa ,Stacie Dusetzina ,Deena Beasley ,Katie Porter ,Joe Biden ,Merck Kgaa Tepmetko ,Josie Kao ,Bristol Myers ,Caroline Humer ,Amgen Inc Lumakras ,Nashville Vanderbilt University Medical Center ,Drug Administration ,Reuters ,Representative Katie Porter ,Inflation Reduction Act ,Vanderbilt University Medical Center ,Pharmaceutical Research ,Takeda Pharmaceutical ,Amgen Inc ,Reporting By Deena Beasley ,